Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for P...
Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukes’ C Colon Cancer: Economic Evaluation in an Italian NHS Setting
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Background and objective:
In the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda®) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with Dukes’ C colorectal cancer. We used the X-ACT results to determine the cos...
Alternative Titles
Full title
Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukes’ C Colon Cancer: Economic Evaluation in an Italian NHS Setting
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_224990150
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_224990150
Other Identifiers
ISSN
1173-2563
E-ISSN
1179-1918
DOI
10.2165/00044011-200828100-00005
